SkinBioTherapeutics Plc

As of December 31, 2025, SkinBioTherapeutics Plc carries a market capitalization of 4.08B, placing it among publicly traded companies globally. Its enterprise value stands at 3.86B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

SkinBioTherapeutics Plc's next confirmed earnings release is scheduled for December 2, 2026.

As of December 31, 2025, SkinBioTherapeutics Plc has 258.78M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, SkinBioTherapeutics Plc maintains a current ratio of 6.14, meaning it holds 6.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, SkinBioTherapeutics Plc's stock has declined approximately 61.90% over the past 52 weeks. The 50-day moving average sits at 7.72, while the 200-day moving average is 11.84.

As of December 31, 2025, SkinBioTherapeutics Plc holds 312.47M in cash and equivalents against 93.92M in total debt, resulting in a net debt position of -252.47M. Total book value stands at 797.82M, with working capital of 402.45M providing operational flexibility.

SkinBioTherapeutics Plc's most recent stock split took place on October 14, 2020.